Kenvue Inc. (NYSE:KVUE) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 78.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,772,963 shares of the company's stock after buying an additional 779,683 shares during the period. Natixis Advisors LLC owned approximately 0.09% of Kenvue worth $41,008,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Mizuho Markets Americas LLC raised its holdings in shares of Kenvue by 464.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,810,403 shares of the company's stock valued at $41,875,000 after purchasing an additional 1,489,647 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund grew its position in Kenvue by 2.0% during the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 56,703 shares of the company's stock worth $1,312,000 after purchasing an additional 1,114 shares during the last quarter. Kentucky Retirement Systems boosted its holdings in shares of Kenvue by 2.7% in the 3rd quarter. Kentucky Retirement Systems now owns 133,421 shares of the company's stock valued at $3,086,000 after acquiring an additional 3,548 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Kenvue by 16.0% in the 3rd quarter. Empowered Funds LLC now owns 149,371 shares of the company's stock valued at $3,455,000 after acquiring an additional 20,593 shares during the last quarter. Finally, Empirical Finance LLC boosted its holdings in shares of Kenvue by 12.0% in the 3rd quarter. Empirical Finance LLC now owns 25,341 shares of the company's stock valued at $586,000 after acquiring an additional 2,721 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Down 0.4 %

KVUE stock traded down $0.09 during mid-day trading on Monday, hitting $23.73. 14,591,632 shares of the company were exchanged, compared to its average volume of 18,038,559. The business has a fifty day simple moving average of $22.77 and a 200-day simple moving average of $20.71. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.13. The firm has a market capitalization of $45.50 billion, a P/E ratio of 43.24, a PEG ratio of 2.16 and a beta of 1.36.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.31 earnings per share. On average, equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.46%. Kenvue's dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of a number of recent analyst reports. Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. UBS Group increased their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. JPMorgan Chase & Co. upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.